In 2007, researchers noticed that the anti-HIV drug nelfinavir, developed in the 1990s, had a surprising second benefit. It reduced tumor size in a variety of cancers. Now, scientists think they have figured out how nelfinavir and other drugs work their double magic. Instead of strongly inhibiting one enzyme like most drugs on the market, they act weakly against many targets. "This is part of a pa